These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 34495377)
1. The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment. Ahmed I; Liu TYA Curr Diab Rep; 2021 Sep; 21(10):40. PubMed ID: 34495377 [TBL] [Abstract][Full Text] [Related]
2. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes. Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690 [TBL] [Abstract][Full Text] [Related]
3. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329 [TBL] [Abstract][Full Text] [Related]
4. Patient Perceptions of SARS-CoV-2 Exposure Risk and Association With Continuity of Ophthalmic Care. Lindeke-Myers A; Zhao PYC; Meyer BI; Liu EA; Levine DA; Bennett OM; Ji S; Newman-Casey PA; Rao RC; Jain N JAMA Ophthalmol; 2021 May; 139(5):508-515. PubMed ID: 33704358 [TBL] [Abstract][Full Text] [Related]
5. The Effect of Delay in Care among Patients Requiring Intravitreal Injections. Song W; Singh RP; Rachitskaya AV Ophthalmol Retina; 2021 Oct; 5(10):975-980. PubMed ID: 33395587 [TBL] [Abstract][Full Text] [Related]
6. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes. Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179 [TBL] [Abstract][Full Text] [Related]
7. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines. Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306 [TBL] [Abstract][Full Text] [Related]
8. Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies. Sun JK; Wang PW; Taylor S; Haskova Z Ophthalmology; 2019 May; 126(5):712-720. PubMed ID: 30419298 [TBL] [Abstract][Full Text] [Related]
9. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945 [TBL] [Abstract][Full Text] [Related]
10. Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept. Blindbæk SL; Peto T; Grauslund J Ophthalmic Res; 2020; 63(2):106-113. PubMed ID: 31715608 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy. Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773 [TBL] [Abstract][Full Text] [Related]
12. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE. Pieramici DJ; Wang PW; Ding B; Gune S Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841 [TBL] [Abstract][Full Text] [Related]
13. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes. Bahrami B; Hong T; Schlub TE; Chang AA Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767 [TBL] [Abstract][Full Text] [Related]
14. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT. Ozsaygili C; Duru N Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970 [TBL] [Abstract][Full Text] [Related]
15. Situational analysis of diabetic retinopathy screening in India: How has it changed in the last three years? Murthy GVS Indian J Ophthalmol; 2021 Nov; 69(11):2944-2950. PubMed ID: 34708728 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal cortisone injection for refractory diffuse diabetic macular edema. Er H; Yilmaz H Ophthalmologica; 2005; 219(6):394-400. PubMed ID: 16286802 [TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. Busch C; Fraser-Bell S; Zur D; Rodríguez-Valdés PJ; Cebeci Z; Lupidi M; Fung AT; Gabrielle PH; Giancipoli E; Chaikitmongkol V; Okada M; Laíns I; Santos AR; Kunavisarut P; Sala-Puigdollers A; Chhablani J; Ozimek M; Hilely A; Unterlauft JD; Loewenstein A; Iglicki M; Rehak M; Acta Diabetol; 2019 Jul; 56(7):777-784. PubMed ID: 30903434 [TBL] [Abstract][Full Text] [Related]
18. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ip MS; Domalpally A; Sun JK; Ehrlich JS Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595 [TBL] [Abstract][Full Text] [Related]
19. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Ip MS; Domalpally A; Hopkins JJ; Wong P; Ehrlich JS Arch Ophthalmol; 2012 Sep; 130(9):1145-52. PubMed ID: 22965590 [TBL] [Abstract][Full Text] [Related]